GSK Acquires Boston Pharmaceuticals’ Liver Drug for $1.2 Billion Plus

GSK has agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready, potential best-in-class, investigational drug for steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totaling $800 million. Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of fibroblast […]